

**Present:**

Mrs M Eastwood	
Dr R Patmore	Hull and East Yorkshire Hospitals NHS Trust
Mr S Ljubojevic	Humber & Yorkshire Coast Cancer Research Network
Ms H Mitchell	Humber and Yorkshire Coast Cancer Network
Ms H Dickinson	Leeds Teaching Hospitals NHS Trust
Dr D Gilson	
Dr R Johnson (Chair)	
Dr D Wright	Mid Yorkshire Hospitals NHS Trust
Miss L Carroll	Yorkshire Cancer Network
Mr P Melling	
Mrs A Millett	
Mr D Thomson	

**Apologies**

Dr S Ali, Dr D Bowen, Dr G Bynoe, Dr A Critchley, Dr G Dublon, Mr S Duffy, Dr A Edwards, Dr M Gesinde, Dr A Hill, Dr P Hillmen, Dr A Jack, Mr B Tinkler

<b>2. Action Log from the last meeting</b>			
Log No	Action	Lead(s)	Deadline
<b>21</b>	The Action Log of the last meeting was agreed as an accurate record.  Dr Johnson thanked Dr Patmore on behalf of the group for his time as Chair.	N/A	N/A
<b>3. Matters arising</b>			
<b>3.1 TYA Guidelines Group update</b>			
Log No	Action	Lead(s)	Deadline
<b>22</b>	Dr Gilson met with Sister Morgan to discuss the review of the TYA guidelines.  The primary treatment centre will remain as Leeds and serve both Networks (HYCCN and YCN). There are plans to have a subsidiary unit for the HYCCN which will be integrated with the primary centre.  The rescheduled Draft Children's Cancer Measures Consultation Workshop has been cancelled awaiting the publication of the final Quality Measures.  To update the current TYA guidelines and send to Dr Gilson for circulation to the group.	S Morgan and D Gilson	Review 19/12/2008

<b>3. Matters arising</b>			
<b>3.2 Excellence in decision making process</b>			
Log No	Action	Lead(s)	Deadline
<b>23</b>	<p>The SHA is leading on the Excellence in decision making process. The SHA is employing York and Sheffield Universities to undertake full health technology appraisals. The three Networks (HYCCN, YCN and NTCN) have been asked to submit suggestions for review against their criteria. Lenalidomide and Thalidomide have been accepted for review.</p> <p>The mandate has been given to the three Networks to advise the Specialist Commissioning Group on all cancer drugs. The first meeting of the tri-Network advisory group will take place in October 2008. This tri-Network group will horizon scan new drugs, debate and recommend to the SCG commissioning policies for the implementation of new drugs and identify criteria for exceptional case consideration.</p> <p>A paper has been produced for consultation by the YCN Management Board.</p> <p>To feedback after the October YCN Management Board meeting.</p>	D Thomson	Review 19/12/2008
<b>3.3 GCSF</b>			
Log No	Action	Lead(s)	Deadline
<b>24</b>	There is a regional tender for GCSF. Each Trust has their own policy which is being monitored on a ongoing basis by the procurement team.	N/A	N/A
<b>3.4 Biopsy's for lymphomas - policy</b>			
Log No	Action	Lead(s)	Deadline
<b>26</b>	<p>Dr Johnson agreed to contact Dr Jack to see if he can produce a draft policy on biopsy's for lymphomas prior to the next meeting.</p> <p>* Since the meeting Dr Johnson has asked Andrew Jack to look at this policy for the next meeting*</p>	R Johnson and A Jack	19/12/2008
<b>3.5 Velcade</b>			
Log No	Action	Lead(s)	Deadline
<b>25</b>	<p>It has previously been agreed that MDTs would collect the exceptions data and this will be reviewed on a three monthly basis.</p> <p>Mr Thomson to ask MDTs for update on exceptions and feedback at the next meeting.</p>	D Thomason	19/12/2008
<b>3.6 PET-CT</b>			
Log No	Action	Lead(s)	Deadline
<b>27</b>	<p>Dr Johnson ensured members had received the summary of discussion for the Network PET Lymphoma meeting that took place on 27th June 2008.</p> <p>This will be discussed and formally agreed at the Lymphoma guidelines meeting taking place n 26th September 2008.</p> <p>To inform Miss Carroll when the PET-CT guidelines have been formally approved.</p> <p>**The PET guidelines were agreed at the lymphoma guidelines meeting and they will be updated and circulated by Abraham Varghese**</p>	R Johnson	Review 19/12/2008

<b>3. Matters arising</b>			
<b>3.7 Vice Chair</b>			
Log No	Action	Lead(s)	Deadline
<b>28</b>	<p>The ToR state that a member of the HYCCN will take on the role as Chair every third term of office.</p> <p>The new Vice Chair should therefore be a representative from the YCN.</p> <p>Dr Patmore agreed to represent the Haematology NSSG at the HYCCN meetings and feedback.</p> <p>To send nominations for Vice Chair to Miss Carroll.</p>	All	Review 19/12/2008
<b>4. Regional Guidelines</b>			
<b>4.1 Leukaemia Guidelines Meeting - 11th July</b>			
Log No	Action	Lead(s)	Deadline
<b>29</b>	<p>The Leukaemia guidelines review meeting took place on 11th July 2008.</p> <p>Abraham Varghese is updating these guidelines.</p> <p>Dr Johnson to contact Abraham Varghese to confirm when the guidelines will be ready for circulation.</p>	R Johnson	19/12/2008
<b>4.2 Lymphoma/Myeloma Guidelines Meeting - 26th September 2008</b>			
Log No	Action	Lead(s)	Deadline
<b>30</b>	<p>Dr Patmore confirmed that the regimens were discussed at the Leukaemia guidelines review meeting.</p> <p>Mr Thomson to send the list of chemotherapy regimens for consideration at the Lymphoma/Myeloma guidelines meeting taking place on 26th September 2008.</p>	D Thomson	26/09/2006
<b>5. Haematology Audit Group</b>			
Log No	Action	Lead(s)	Deadline
<b>31</b>	<p>The next Haematology audit group meeting is taking place on 19th September 2008.</p> <p>Dr Patmore reported that very few people have accessed the EGU website and encouraged colleagues to do so. This website will be officially launched at the EGU educational event taking place on Friday 19th September.</p> <p>To keep members updated on the work of the audit group.</p>	R Patmore	Review 19/09/2008
<b>6. New Cancer Peer Review Process</b>			
Log No	Action	Lead(s)	Deadline
<b>32</b>	<p>It is anticipated the launch of the new Peer Process will take place at the NDP in October 2008. The new process will involve a self assessment followed by a local validation process (this is yet to be agreed but could be Network Representatives, Trust Cancer Lead, Commissioning representative). A sample of these will then be externally reviewed by Zonal teams. A targeted visit will take place for those that have requested one or when it is felt there is a need for one.</p>	N/a	N/A

<b>6. New Cancer Peer Review Process</b>			
<b>6.1 Calderdale and Huddersfield NHS Foundation Trust</b>			
Log No	Action	Lead(s)	Deadline
<b>33</b>	<p>Dr Johnson has discussed C&amp;H NHS Foundation Trust with Ms A Walton. It is felt that the Peer Review process will improve the MDT process however staff capacity is still a major issue.</p> <p>The possibility of Bradford and Calderdale &amp; Huddersfield linking MDTs was suggested.</p> <p>Members agreed this needs discussing formally.</p>	R Johnson	Review 19/12/2008
<b>7. User Involvement</b>			
Log No	Action	Lead(s)	Deadline
<b>34</b>	<p>Ms Lesley Wood has been nominated to be User Involvement and Patient Information Lead.</p> <p>This was confirmed at the Nurses meeting that took place on Wednesday 10th October 2008.</p> <p>To send the role description and further details to Ms Wood.</p>	L Carroll	12/09/2008
<b>8. Nursing</b>			
Log No	Action	Lead(s)	Deadline
<b>35</b>	<p>The Haematology Nurses are holding a workshop on Wednesday 10th October to include the nursing elements to the draft pathways on ALL, MDS, MPD and lymphoma. The nurses hope to develop pathways for AML and Myeloma at a future meeting.</p> <p>Mrs Millett summarised the Quality criteria for the pathways.</p> <p>To keep members updated on the work of the nurses group.</p>	M McHugh	19/12/2008
<b>9. Cancer Waiting Times</b>			
Log No	Action	Lead(s)	Deadline
<b>36</b>	<p>Mr Melling presented the latest CWT data.</p> <p>A Going Further on Cancer Waits workshop to support the new CWT standards is taking place on Tuesday 16th September 2008 at Weetwood Hall, Leeds.</p> <p>The HYCCN workshop is taking place on Tuesday 23rd September 2008.</p>	P Melling/H Mitchell	19/12/2008
<b>10. Network pathway Development update</b>			
Log No	Action	Lead(s)	Deadline
<b>37</b>	<p>See 8. Nursing.</p> <p>Mrs Millett informed members that the YCN are working with Leeds on their reproductive units pathways for cancer. A paper describing the current service is going to the YCN Management Board in October 2008. Mrs Millett asked if there were any issues/ideas regarding improvement of this service.</p> <p>To consider funding and long term storage issues when undertaking this work.</p>	A Millett	Review 19/12/2008

**Haematology Group : Actions of the meeting held on Friday 5th September 2008 2:00 pm**

<b>11. YCRN &amp; HYCCRN</b>			
Log No	Action	Lead(s)	Deadline
<b>38</b>	To keep members updated on the work of the YCRN and HYCRN.	HYCRN and YCN	19/12/2008
<b>13. Any Other Business</b>			
Log No	Action	Lead(s)	Deadline
<b>39</b>	<p>The HYCCN and YCN Children and Young People Haematology and Oncology Group are holding their Educational Event on 14th November 2008.</p> <p>The annual NCRI Lymphoma day is also taking place on 14th November 2008.</p> <p>The NCRI are holding a conference on 5-8th October 2008 in Birmingham.</p> <p>The intrathecal guidance is being updated by the YCN.</p>	N/A	N/A

**Date of Next Meeting(s)**

Friday 19th September 2008 9:30 am  
National Science Learning Centre, University of York [Educational Event]

Friday 19th December 2008 2:00 pm  
Lecture Room, Cookridge Suite, Level 7, Bexley Wing, St James's University Hospital

Friday 6th March 2009 2:00 pm  
TBC

Friday 12th June 2009 2:00 pm  
TBC

Friday 18th September 2009 2:00 pm  
TBC